Cargando…

Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab

PURPOSE: We aimed to determine and compare the predictive values of depth of response (DpR) and early tumor shrinkage (ETS) on long-term outcomes in gastric cancer patients treated with trastuzumab. RESULTS: From a total of 368 computed tomography examinations, DpR and ETS were evaluated. DpR was a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Choong-Kun, Kim, Seung-Seob, Park, Saemi, Kim, Chan, Heo, Su Jin, Lim, Joon Seok, Kim, Hyunki, Kim, Hyo Song, Rha, Sun Young, Chung, Hyun Cheol, Park, Sohee, Jung, Minkyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458198/ https://www.ncbi.nlm.nih.gov/pubmed/28415714 http://dx.doi.org/10.18632/oncotarget.16099

Ejemplares similares

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
por: Lee, Choong-kun, et al.
Publicado: (2022)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Probe-Based Confocal Laser Endomicroscopy versus White-Light Endoscopy with Narrow-Band Imaging for Predicting and Collecting Residual Cancer Tissue in Patients with Gastric Cancer Receiving Chemotherapy
por: Kim, Yuna, et al.
Publicado: (2022)

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy
por: Jung, Minkyu, et al.
Publicado: (2012)

Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells
por: Kim, Yuna, et al.
Publicado: (2023)

Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
por: Jung, Seung-Hyun, et al.
Publicado: (2023)

Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
por: Lee, Choong-kun, et al.
Publicado: (2015)

Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
por: Park, Hyung Soon, et al.
Publicado: (2019)

Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
por: Kim, Min Hwan, et al.
Publicado: (2019)

Prognostic Significance of ARID1A Expression Patterns Varies with Molecular Subtype in Advanced Gastric Cancer
por: Kim, Jun Yong, et al.
Publicado: (2023)

Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
por: Kim, Chang Gon, et al.
Publicado: (2023)

Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia
por: Chon, Hong Jae, et al.
Publicado: (2017)

Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy
por: Kim, Hyo Song, et al.
Publicado: (2016)

Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm
por: Park, Cheol Keun, et al.
Publicado: (2016)

Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
por: Kim, Hyo Song, et al.
Publicado: (2017)

Multicentric Type 3 Gastric Neuroendocrine Tumors
por: Lee, Sang Hoon, et al.
Publicado: (2015)

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
por: Jung, Minkyu, et al.
Publicado: (2012)

Sample Collection Methods in Upper Gastrointestinal Research
por: Yang, Hyo-Joon, et al.
Publicado: (2023)

A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
por: Yi, Jun Ho, et al.
Publicado: (2016)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2021)

Predictors of Good Outcomes in Patients with Failed Endovascular Thrombectomy
por: Park, Hyungjong, et al.
Publicado: (2020)

Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
por: Park, Won-Young, et al.
Publicado: (2016)

Detection of asymptomatic recurrence improves survival of gastric cancer patients
por: Park, Ji Soo, et al.
Publicado: (2021)

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
por: Lee, Choong-kun, et al.
Publicado: (2019)

Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
por: Seo, An Na, et al.
Publicado: (2016)

Visceral Adiposity as a Significant Predictor of Sunitinib-Induced Dose-Limiting Toxicities and Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma
por: Park, Jee Soo, et al.
Publicado: (2020)

A Case of Nocardia farcinica Pneumonia and Mediastinitis in an Immunocompetent Patient
por: Kim, Jinyoung, et al.
Publicado: (2016)

Prognostic significance of preoperative CT findings in patients with advanced gastric cancer who underwent curative gastrectomy
por: Park, Chae Jung, et al.
Publicado: (2018)

Retention Esophagitis as a Significant Clinical Predictor of Progression to Esophageal Cancer in Achalasia
por: Kim, Haewon, et al.
Publicado: (2018)

The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
por: Lee, Ji Yun, et al.
Publicado: (2015)

The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients
por: Lee, Choong-kun, et al.
Publicado: (2022)

Point of care airway ultrasound to select tracheal tube and determine insertion depth in cleft repair surgery
por: Ahn, Jung Hwan, et al.
Publicado: (2021)

Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
por: Beom, Seung-Hoon, et al.
Publicado: (2018)

Prognostic significance of T‐cell–inflamed gene expression profile and PD‐L1 expression in patients with esophageal cancer
por: Steiniche, Torben, et al.
Publicado: (2021)

Psoriasis Induced by Trastuzumab (Herceptin®)
por: Kim, Dae Hun, et al.
Publicado: (2013)

Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment
por: Kwon, Hyun Jung, et al.
Publicado: (2023)

Significance of Microalbuminuria in Relation to Subclinical Coronary Atherosclerosis in Asymptomatic Nonhypertensive, Nondiabetic Subjects
por: Park, Hyo Eun, et al.
Publicado: (2013)

Prognostic effect of perineural invasion in surgically treated esophageal squamous cell carcinoma
por: Kim, Ha Eun, et al.
Publicado: (2021)

Out-of-Hospital Cohort Treatment of Coronavirus Disease 2019 Patients with Mild Symptoms in Korea: an Experience from a Single Community Treatment Center
por: Park, Peong Gang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mc2vilut4a9b7v0e15jbdin0ak